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Abstract. The delivery of therapeutic nucleic acids to neurons has the potential to treat neurological
disease and spinal cord injury. While select viral vectors have shown promise as gene carriers to neurons,
their potential as therapeutic agents is limited by their toxicity and immunogenicity, their broad tropism,
and the cost of large-scale formulation. Nonviral vectors are an attractive alternative in that they offer
improved safety profiles compared to viruses, are less expensive to produce, and can be targeted to
specific neuronal subpopulations. However, most nonviral vectors suffer from significantly lower
transfection efficiencies than neurotropic viruses, severely limiting their utility in neuron-targeted
delivery applications. To realize the potential of nonviral delivery technology in neurons, vectors must
be designed to overcome a series of extra- and intracellular barriers. In this article, we describe the
challenges preventing successful nonviral delivery of nucleic acids to neurons and review strategies
aimed at overcoming these challenges.
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INTRODUCTION
Inflictions of the central nervous system, including spinal
cord injury and neurodegenerative diseases, are devastating
disorders for which there are currently few treatment
options. Continuing elucidation of the molecular mechanisms
underlying the pathology associated with these disorders will
enable the development of treatment strategies that reverse
neuropathology at the molecular level. Nucleic acid-based
therapy has the potential to address the molecular cause of
neurological disease by manipulating gene expression pro-
files in targeted cells in the central nervous system (CNS).
Although the role of various cell types in CNS disorders is
still being elucidated, this review focuses on neuronal
therapies. Two approaches for nucleic acid-based therapy
which have been studied for the treatment of neurological
disease include gene therapy and gene silencing. CNS-
targeted gene therapy can be accomplished by introducing
genes encoding neurotrophic growth factors or corrective
enzymes to injured or diseased neurons (1–5). In several
animal models of neurodegenerative disease, gene therapy
has achieved dramatic pathologic and functional improve-
ments (6–13). Additionally, gene silencing strategies such as
RNA interference (RNAi) can be implemented to reduce the
expression levels of toxic proteins associated with neurolog-
ical disease, and to minimize growth inhibitory signals
associated with spinal cord injury (14–16). The potential of
RNAi-based therapies for the treatment of neurological
disease has recently been demonstrated in animal models of
spinocerebellar ataxia, Huntington_s disease, amyotrophic
lateral sclerosis, and Alzheimer_s disease (17–20). Examples
of disease-specific nucleic acid therapy approaches are
summarized in Table 1.
Genes packaged in viral vectors, such as adeno-associated
virus (AAV) or herpes simplex virus (HSV), remain the
leading therapeutic candidates for neuron-targeted nucleic
acid therapy, as they have produced functional improvement
in several animal models of neurodegenerative disease. The
few clinical trials that have been undertaken to treat neuro-
degenerative disease have employed viral vectors almost
exclusively. However, significant complications associated
with viral delivery limit its widespread clinical use. For
example, the injection of HSV into mammalian tissue elicits
a local immune response (21). Also, neutralizing antibodies
against AAV in humans may be produced due to previous
exposure (22); this complication has delayed clinical trials
using AAV. Although viral vectors can be genetically
modified to remove viral components that trigger an immune
response, these modified viruses are often difficult to
produce in high titer. Given the shortcomings associated
with the clinical use of viral vectors, a critical need remains
for vectors that deliver therapeutic nucleic acid cargo as
efficiently as viruses, but which are safer to administer in
vivo. Nonviral vectors, which offer improved safety profiles
compared to viruses, represent a promising alternative to
viruses for gene therapy applications. However, to realize the
potential of nonviral gene delivery technology for CNS
delivery applications, the limited transfection efficiencies of
nonviral vectors must be addressed.
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u.washington.edu)NONVIRAL VEHICLES FOR NEURONAL NUCLEIC
ACID DELIVERY
Realizing the potential of nonviral gene therapy to
neurons will require the development of synthetic vectors
that are capable of mediating efficient delivery of
therapeutic nucleic acids into the targeted cells. The ideal
vector will efficiently condense and protect nucleic acid
cargo, target specific neuronal subpopulations in the body,
and mediate appropriate intracellular delivery of the
therapeutics. Toward this goal, research efforts have
focused on evaluating existing vectors and developing
new vectors for efficient neuronal transfection. The
various classes of nonviral carriers that have been
evaluated for neuronal gene delivery are described in
the following sections.
Table 1. Examples of Nucleic Acid Delivery Resulting in Pathologic and/or Behavioral Improvements in Animal Models of
Neurodegenerative Disease
Disease/Model Therapeutic Nucleic Acid Vector/Delivery Location Therapeutic Endpoints Reference
Alzheimer_s
Disease/APP
mouse model
DNA encoding neprilysin Herpes simplex virus/
Hippocampal injection
Pathologic: Reduced
amyloid production
and accumulation
(13)
DNA encoding shRNA
against beta-secretase
Lentivirus/Hippocampal
injection
Pathologic: Reduced
amyloid production and
neuropathology
Behavioral: Ameliorated
behavioral deficits
(20)
Parkinson_s
Disease/6-OHDA
induced rat model
of Parkinson_s
DNA encoding GDNF Adeno-associated virus/
Intranigral injection
Pathologic: Protected
nigral neurons
(8)
Adenovirus/Intrastriatal
injection
Pathologic: Protected
nigral neurons
Behavioral: Prevented
motor impairment
(9)
Neurotensin-polyplex/
Intranigral injection
Pathologic: Protected
nigral neurons
Behavioral: Prevented
motor impairment
(10)
DNA encoding tyrosine
hydroxylase
Herpes simplex virus/
Intrastiatal injection
Pathologic: Increased striatal
tyrosine hydroxylase activity
Behavioral: Reversal of
motor impairment
(12)
PEGylated immunoliposomes/
Intravenous administration
Behavioral: Reversal of
motor impairment
(11)
Amyotrophic Lateral
Sclerosis (ALS)/
SOD1 mouse model
DNA encoding insulin
growth factor 1
Adeno-associated virus/
Intramuscular injection
Pathologic: Delayed
astroglial response
Behavioral: Improved
motor performance and
prolonged survival
(6)
DNA encoding shRNA
against mutant SOD1
Lentivirus/Intramuscular
injection
Pathologic: Improved motor
neuron survival
Behavioral: Improved
motor performance
and prolonged survival
(19)
Huntington_s Disease/
aRats with striatal
lesions;
bHD mouse
model (expresses
mutant huntingtin)
aDNA encoding GDNF or
BDNF
Adeno-associated virus/
Intrastriatal injection
Pathologic: Reduced loss of
striatal neurons
(7)
bDNA encoding shRNA
against mutant huntingtin
Adeno-associated virus/
Intrastriatal injection
Pathologic: Reduced mutant
huntingtin inclusions
Behavioral: Improved gait
and motor coordination
(18)
Spinocerebellar ataxia
(SCA)/SCA1
mouse model
DNA encoding shRNA
against mutant ataxin-1
Adeno-associated virus/
Intracerebellar injection
Pathologic: Reduced ataxin-1
inclusions
Behavioral: Improved
motor coordination
(17)
Examples included in the table are limited to treatment approaches involving in vivo administration of gene vectors, although ex vivo gene
therapy approaches offer promising treatment options for neurological disorders as well.
984 Bergen, Park, Horner, and PunNonviral Carriers for Neuronal Transfection
Polymers
Cationic polymers efficiently condense nucleic acids into
nanoparticles, termed Bpolyplexes,^ by self-assembly via
electrostatic interactions. An attractive feature of many
polymeric vectors is that they contain functional groups that
can be modified with ligands such as cell-targeting molecules
(23). A number of cationic polymers have been studied for
their ability to mediate nucleic acid delivery into neurons,
although poly-L-lysine (PLL) and poly(ethylenimine) (PEI)
are most widely represented in the literature (see Fig. 1 for
polymer structures). PEI was introduced as a versatile
nonviral gene carrier over a decade ago by Boussif et al.
(24). Whereas previously studied polymer-based gene vec-
tors, such as PLL, showed minimal neuronal transfection,
optimized formulations of PEI showed significant reporter
gene expression in cultured chick embryonic neurons and in
newborn mouse brains. The higher gene delivery efficiency of
PEI compared to PLL is attributed to its enhanced endo-
somal release capability (24,25). Abdallah et al.( 26) further
demonstrated that, following direct brain injection in mature
mice, the gene transfer capabilities of PEI-based polyplexes
surpassed those of HIV-derived vectors and were compara-
ble to those of adenoviral vectors. Still, polyplexes and other
nonviral agents are typically less efficient than neurotropic
viruses such as HSV for gene delivery to neurons (27).
Additionally, the tendency of PEI/DNA polyplexes to
aggregate in biological fluids and the cellular toxicity of
PEI limit their potential application toward nucleic acid
therapy. Grafting the hydrophilic polymer poly(ethylene
glycol) (PEG) onto PEI-based polyplexes has been shown
to prevent particle aggregation and reduce cellular toxicity
following administration to the CNS (28,29). To target
polyplexes to specific neuronal subpopulations, polymers
have been modified with cell-targeting ligands, which will
be discussed in more detail later in this article.
Lipids
Cationic lipids are among the most efficient nonviral
vectors, and have been used extensively to transfect cultured
neurons for studies in basic neuroscience. While their transfec-
tionefficiency istypically surpassed by viral vectors,their utility
derives from their ease of use and their large nucleic acid
capacity. The various commercially-available cationic lipid
formulations are typically composed of some combination of a
cationic lipid such as 1,2-dioleoyl-3-trimethylammonium pro-
pane (DOTAP), N-methyl-4-(dioleyl)methylpyridinium
(SAINT-2), 3b-[N-(N¶,N¶-dimethylaminoethane)-carbamoyl]
cholesterol (DC-Chol), or GS1, as well as the neutral lipid
dioleoylphosphatidylethanolamine (DOPE) and cholesterol
(see (30) for a recent review describing cationic lipids and
lipoplexes for gene delivery). The simple addition of
polyanionic nucleic acids to mixtures of cationic lipids or
liposomes results in their self-assembly into particles termed
Blipoplexes.^ While early cationic lipid formulations yielded
approximately 1–3% transfected cells in primary neuronal
cultures (31–33), newer formulations such as LIPOFECTAMINEi
2000 (L2K) afford õ20–25% transfected primary neurons (34).
Despite their relatively efficient transfection of cultured
neurons, the in vivo delivery of cationic lipid-based carriers
has been challenged by their tendency to aggregate in
biological fluids (35). As an alternative, Pardridge (36)
introduced PEGylated immunoliposomes (PILs), which con-
sist of plasmid DNA encapsulated by PEG-modified neutral
lipids. Unlike cationic liposomes, PILs retain colloidal stability
in the blood following intravenous administration. By tether-
ing targeting ligands such as transferrin or antibodies to the
ends of the PEG strands, PILs have been shown to mediate
efficient nucleic acid delivery to neurons in the CNS following
systemic administration (37–39).
Polypeptides/Proteins
Engineered polypeptides are an appealing delivery
platform because they can be designed modularly, incorpo-
rating functionalities for nucleic acid condensation, neuronal
targeting, endosomal escape, and nuclear entry into a single
recombinant protein. Efforts in this area have focused on the
design of recombinant fusion proteins based on the tetanus
toxin fragment C for neuronal targeting with additional
domains for endosomal escape and DNA condensation
mediated by the translocation domain of diphtheria toxin
and the GAL4 transcription factor DNA-binding domain,
respectively (40). Chimeric proteins were more efficient for
transfection of cultured, neuron-like cells than mutants
lacking one or more of the functionalities. Similar strategies
employing nerve growth factor (NGF)-derived targeting
peptides have also been described (41–43). In these studies,
neuron-specific transfection was achieved using chimeric
complexes consisting of either loop 4 of NGF or an NGF
hairpin motif containing loops 1 and 2 fused to a DNA-
binding domain.
Nanoparticles
Recent advances in nanotechnology have inspired the
development of nonviral gene carriers based on synthetic
nanoparticles. As an early example, it was demonstrated that
gold nanoparticles coated with plasmid DNA could be
delivered into cultured neurons through biolistic particle
bombardment (44). However, fewer than 10% of neurons in
primary culture were transfected by this method, and biolistic
particle bombardment is not practical for therapeutic appli-
cations requiring in vivo delivery. Iron oxide nanoparticles
coated with PLL demonstrated better in vivo success, as they
bound DNA and mediated reporter gene expression in
neurons and glia of the brain following intravenous injection
(45). Also, it was recently demonstrated that amino-terminated
organically modified silica (ORMOSIL) nanoparticles com-
plexed with plasmid DNA were capable of transfecting neuronal
cells following intraventricular injection at levels similar to HSV
with fewer toxic or immunological side effects (46).
Naked DNA
In addition to the nonviral carriers for neuronal trans-
fection described in the previous sections, physical methods
have also been employed to efficiently deliver nucleic acids
to cultured neurons. The electroporation-based technique
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Amaxa Biosystems) has demonstrated impressive transfec-
tion efficiencies in primary neurons (47,48). However,
translation of this technique to in vivo applications is
challenged by the need to apply an electrical field in close
proximity to cells, as well as its lack of cell type specificity.
Although it is generally accepted that nucleic acids require
chemical and/or physical means to gain entry into cells, a few
studies have demonstrated the ability of uncondensed, Bnaked^
nucleic acids to mediate gene expression in neurons when
administered in vivo. Notably, naked DNA has been shown to
mediate reporter gene expression in the brain stem following
either intramuscular injection in the tongue or intracisternal
injection (49,50). Additionally, naked plasmid DNA has been
shown to mediate low levels of reporter gene expression in
neurons and astrocytes when delivered to sites of spinal cord
Fig. 1. Structures of common polymers and lipids used as nonviral gene vectors. Cationic polymers include poly (L-lysine) (PLL) and
poly(ethylenimine) (PEI). 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) is a cationic lipid and dioleoylphosphatidylethanolamine
(DOPE) is a neutral Bhelper^ lipid often included in cationic lipid formulations.
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transfection in the CNS warrants further investigation.
In vivo Successes
While a number of nonviral vectors, described in the
previous section, have mediated reporter gene expression in
the CNS of animal models, only a few of these systems have
been successfully applied toward animal models of neurolog-
ical disease or injury. Notably, several nonviral gene delivery
approaches have been validated in animal models of
Parkinson_s disease. For example, Zhang et al.( 11) showed
that intravenous administration of PEGylated immunolipo-
somes mediated brain-specific delivery of a gene encoding
tyrosine hydroxylase (TH), resulting in reversal of motor
impairment. Recently, polyplexes incorporating a plasmid
encoding human GDNF as well as ligands for receptor
targeting and intracellular trafficking were injected into the
substantia nigra of hemiparkinsonian rats, resulting in
therapeutic levels of GDNF expression and a reversal of
motor impairment (10). These studies have validated nonvi-
ral delivery as a viable alternative for CNS gene therapy.
Additional studies have demonstrated the potential of
nonviral vectors to mediate functional improvement in models
of nerve and brain injury. For example, Barati et al.( 52)
delivered a plasmid encoding GDNF to injured nerves using a
neurotrophin receptor-targeted, PLL-based polyplex and dem-
onstrated an almost complete reversal in neuronal death
caused by GDNF transgene expression. The expression of
NGF in the dorsal root ganglia following intrathecal injection
of PEI/DNA complexes has also led to regeneration of
transected peripheral nerves (53). Finally, cationic lipid-based
vectors targeted to transferrin receptors have been shown to
ameliorate morphological damage in a model of brain injury
through low levels of NGF expression in the striatum (54).
Limitations of Current Technology
While the in vivo successes with nonviral vectors to date
are encouraging, improvements in nonviral formulations are
critical before they can be broadly applied toward the
treatment of neurological disease and injury. One issue that
remains to be addressed is the relatively low transfection
efficiency mediated by nonviral carriers compared to neuro-
tropic viruses. Several of the disease conditions treated by
nonviral delivery systems, described in the previous section,
responded to very small amounts of the secreted transgenes
GDNF or NGF. For diseases caused by either toxic gain-
of-function mutations or loss-of-function mutations that
cannot be corrected by the introduction of secreted factors,
more efficient nonviral vectors will be required.
Another important consideration is the duration of
transgene expression afforded by nonviral delivery systems.
Whereas PEI-mediated neuronal transfection results in
expression lasting several days to several weeks (26,55),
select viral vectors have been shown to mediate transgene
expression in neurons that lasts up to half a year (56,57). One
explanation for the relatively short duration of transgene
expression following injection of PEI/DNA polyplexes into
the brain is the toxicity associated with overloading cells with
foreign DNA. To test this hypothesis, Lemkine et al.( 58)
injected various polyplex dosages into the brains of newborn
mice and found a dosage optimum above which the duration
of transgene expression was reduced. Additionally, it was
demonstrated that co-delivery of a reporter gene with bcl-
X(L), an anti-apoptotic gene, significantly increased expres-
sion levels of both genes after 1 week, suggesting that high
polyplex dosages lead to apoptosis.
Broader application of nonviral gene delivery toward
additional models of neurodegenerative disease and injury,
and its eventual translation into the clinic, awaits the
development of formulations with improved transfection
profiles. Future progress will depend on characterizing the
physiological barriers encountered by nonviral carriers,
systematically testing formulations, and integrating knowl-
edge of the multiple barriers encountered into rationally
designed nonviral gene carriers. As described in the subse-
quent sections, a thorough understanding of the intra- and
extracellular barriers encountered by nonviral vectors may
lead to the development of more effective delivery strategies.
INTRACELLULAR BARRIERS ENCOUNTERED
BY GENE CARRIERS IN NEURONS
Neurons are a notoriously difficult cell type to transfect,
both in vitro and in vivo (59,60). This is due, in part, to the
multiple biological barriers that vehicles must overcome in
the intracellular milieu. The most challenging intracellular
route is encountered by vectors delivered to the distal ends of
neuronal projections. In order to successfully transfect
neurons, vectors must bind to the neuronal cell surface, enter
the neuron by endocytosis, and travel toward the nucleus
(Fig. 2). Upon vesicular escape, vectors must mediate
delivery of therapeutic cargo to the appropriate cellular
compartment: the neuronal nucleus, for plasmid DNA
encoding a therapeutic gene, or the perinuclear region of
the cytoplasm, for siRNA. While numerous nonviral vectors
have been developed and studied for their ability to deliver
genetic material to neurons in culture and in vivo, few studies
have investigated and characterized the intracellular barriers
encountered by these vectors. The following sections detail
each of the intracellular barriers potentially encountered by
neuron-targeted nonviral vectors and describe efforts aimed
at overcoming these barriers.
Cell Targeting and Binding
Association with the neuronal plasma membrane is
required for internalization of vectors into the cell. While
nonviral vectors can associate with most cell types via
nonspecific binding to the cell surface, neuron-specific
targeting strategies based on receptor-ligand interactions
are preferable to prevent widespread delivery to off-target
cells. Neurons express a number of different classes of
receptors, including neuropeptide, neurotrophin, and neuro-
toxin receptors (summarized in Table 2). Targeting moieties
corresponding to each of these classes of receptors have been
tested in nonviral delivery systems. As an early example of a
neuron-targeted polyplex, Martinez-Fong et al. conjugated
neurotensin (NT), a 13-amino acid neuropeptide, to PLL,
and demonstrated targeted uptake in cultured cells (61). In
subsequent work, the delivery vector was improved by
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and the Vp1 nuclear localization signal; these targeted gene
carriers could be applied toward the treatment of Parkinson_s
disease, as the high-affinity neurotensin receptor is expressed
predominantly in the nigrostriatal and mesolimbic dopami-
nergic systems (62).
Neurotrophin receptors are an attractive target for
neuron-targeted polyplexes because they are expressed by
specific neuron subtypes, including dorsal root ganglia,
sympathetic neurons, and basal forebrain cholinergic neu-
rons. Various strategies have been described for targeting
polymer-based gene carriers to either TrkA or the p75
NTR
receptors for NGF. Zeng et al.( 63) formulated ternary
complexes by electrostatic association of plasmid DNA, low
molecular weight PEI, and the nerve growth factor loop 4
hairpin motif. These complexes mediated specific gene
transfer into cultured cells expressing the TrkA receptor as
well as into dorsal root ganglia in vivo, while minimizing the
toxicity caused by nonspecific uptake of large amounts of
higher-molecular weight PEI. In addition to targeting
receptors expressed by specific neuronal populations, it
would be ideal to target receptors whose upregulation corre-
sponds to specific disease or injury states. To demonstrate this
strategy, Barati et al.( 52) conjugated an antibody that binds
to the p75
NTR neurotrophin receptor (MC192) to PLL-based
polyplexes and demonstrated transgene expression in target-
ed neurons in models of peripheral nerve injury.
As a final class of neuron-targeting ligands, neurotoxins
have been exploited for their ability to efficiently hijack cel-
lular internalization machinery as a means to invade targeted
neurons. Of particular interest is tetanus toxin (TeNT), which
undergoes efficient retrograde transport in motor neurons
following internalization at presynaptic terminals. The puri-
fied,recombinantheavychainfragmentofTeNT(TTC),which
is responsible for TeNT cell binding and retrograde axonal
transport, has been conjugated to PLL as a means to direct
polyplexesinto celllinesexpressingtherelevantreceptors(64).
Recently, Liu et al.( 65) identified a 12-amino acid peptide,
Tet1, that mimics the receptor binding properties of TTC.
Our group has conjugated this peptide to PEI and demon-
strated specific uptake of Tet1-modified PEI/DNA polyplexes
by cells expressing receptors for TTC (66).
These studies demonstrate that specific neuronal sub-
populations can be targeted for transfection by ligand-
modified polyplexes. Targeted delivery has the ability to
improve the biodistribution of transgene expression caused
by PEI-based vectors, since untargeted polyplexes have been
shown to cause transfection of both neuronal and non-
neuronal cell types in the CNS (26). Targeting studies with
non-viral vectors have been facilitated by the ease with which
primary amine-containing polymers, such as PEI and PLL,
can be linked to targeting moieties via chemical conjugation.
Although the transfection efficiencies mediated by neuron-
targeted, polymer-based carriers are limited compared to
viruses, their advantage is in their cell-targeting specificity.
Nonspecific Binding and Uptake
In addition to receptor-mediated uptake, direct adminis-
trationof cationic vectors totargeted cellpopulations can result
in nonspecific cell association through interactions with anionic
membrane proteins such as proteoglycans (67)( F i g .3). This
strategy has been employed for transfection of neurons in
culture and in the CNS (24,26,55). Understanding and pre-
dicting the efficiency of nonspecific neuronal uptake is com-
plicated by the fact that neurons are a highly polarized cell
type with somal, axonal, and dendritic domains having distinct
membrane compositions (68,69). Further, the physicochemical
Fig. 2. A series of intracellular barriers is encountered by nonviral gene
carriersinneurons.(A)S u c c e s s f u lv e h i c l e sm u s tb ea b l et o( 1)a s s o c i a t e
with the neuronal plasma membrane, (2) undergo internalization, (3a)
escape endosomes, and (4) deliver nucleic acids to the nucleus (a)o r
cytoplasm (b). (B) If vehicles arrive at the axon terminus, they must
additionally undergo retrograde axonal transport (3b).
Table 2. Neuron-Targeting Ligands and their Incorporation into Nonviral Vectors
Ligand Class Example Ligand Neuronal Populations Targeted References
Neuropeptides Neurotensin Nigrostriatal and mesolimbic
dopaminergic system
(61,62)
Neurotrophins Nerve growth factor (NGF) Dorsal root ganglia, sympathetic
sensory neurons, basal forebrain
cholinergic neurons
(52,63)
Neurotoxins Tetanus toxin (TeNT) All peripheral neurons (autonomic,
motor, and sensory)
(64–66)
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surface composition, may strongly influence the nature of their
interaction with the neuronal plasma membrane. Additionally,
the efficiency of cell binding and internalization is likely to
depend on the cell type. Suk et al.( 70) described reduced
uptake of PEI/DNA complexes by differentiated, neuron-like
cells as compared to undifferentiated cells. They speculated
that this was due to a difference in heparan sulfate density on
the surfaces of differentiated versus undifferentiated cells (71).
We have also shown that binding and internalization of
cationic lipid-based gene carriers is more efficient at neuronal
soma than at neurites (72). Consequently, the efficiency of
internalization of nonviral gene carriers may differ depending
on the cell type, the delivery site, and the specific vehicle
formulation.
Vesicular Escape
Regardless of the mechanism or location of entry, gene
carriers that are internalized within neurons are typically
sequestered in vesicles. Vesicles that are part of the endo-/
lysosomal pathway will acidify and eventually fuse with
lysosomes in the neuronal soma to degrade their contents.
Both polyplexes and lipoplexes delivered to neurite terminals
of NGF-differentiated PC-12 cells undergo internalization
within vesicles, demonstrated by co-localization of labeled
vectors with fluid phase uptake markers (72).Thepoor ability
of nonviral gene carriers to escape vesicles following internal-
ization in neurons and their subsequent degradation in
lysosomal compartments may explain their significantly re-
duced transfection efficiencies compared to viruses, which
have been shown to efficiently escape vesicles in neurons (73).
Clearly, the design of improved nonviral gene carriers
must incorporate elements that mediate vesicular escape
prior to degradation of materials in endo-/lysosomal com-
partments. Strategies that promote endosomal escape include
the use of PEI-based carriers, which are believed to buffer
acidifying endosomes and mediate vesicular escape through
osmotic swelling (known as the proton sponge effect), as well
as the incorporation of peptides designed to disrupt the
endosomal membrane (25,74). For lipid-based carriers, the
incorporation of DOPE can facilitate endosomal escape, as it
undergoes a pH-triggered phase transition which can lead to
endosomal membrane disruption (75). The location of
vesicular escape is also important and may depend on the
initial delivery site (soma versus neurites). While carriers
internalized at cell soma may escape vesicles in close
proximity to their ultimate subcellular destination, carriers
that escape prematurely from axonal or dendritic vesicles
face another challenge, efficient trafficking to cell soma.
Retrograde Axonal Transport
Retrograde transport of non-viral vectors following
uptake into mammalian cells has been described, and several
recent studies have investigated this process in neuronal cells
(72,73,76). Wang et al.( 55) demonstrated the capability of
PEI/DNA complexes to undergo internalization within axon
terminals in the tongue and retrograde transport back to
neuronal soma in the brain stem. Using particle tracking, Suk
et al.( 73) directly observed the retrograde transport of
labeled PEI/DNA complexes in live primary neurons. We
have also analyzed retrograde transport of polyplexes
following localized delivery to the distal ends of neurites in
a microfluidic, compartmented culture model that mimics
peripheral delivery (72). However, the movement observed
in most systems is due to transport within endosomes, which
areknowntoacidifyanddegradetheircontentsuponarrivalat
the microtubule-organizing center. In gene delivery systems
that effectively bypass degradation by releasing their cargo
from early endosomes, transport within the cytoplasm is likely
to be a major rate-limiting step due to limited diffusion of
particles >30 nm in size (77). This is especially true for vectors
that escape from vesicles within the axon (Fig. 4).
Cells have developed a highly complex transport infra-
structure that conveys diffusion-limited cargo along cytoskel-
etal filaments. Microtubule-based transport is critical for
neuronal function since it allows communication between the
cell body and axon. For retrograde transport toward the
nucleus, dynein is the primary minus end-directed motor (78,
79). Several viruses take advantage of this retrograde
transport system for delivery of viral proteins and nucleic
acids to the nucleus (80–84). Dynein-mediated transport is a
critical process in the infection cycle of neurotropic viruses
such as HSV and adenovirus (85). The fact that viral
particles, which are similar in size to non-viral gene carriers,
recruit the dynein motor for assisted retrograde transport
validates the need to develop nonviral vectors that can also
actively recruit the retrograde motor machinery for efficient
delivery to neurons.
Despite the clear need for a retrograde transport moiety,
linking artificial cargo to the dynein motor complex has
proven challenging. The development of a dynein-binding
moiety to facilitate retrograde transport of therapeutic cargo
in cells has been proposed (86,87), but a feasible method for
the linkage of synthetic cargo to the dynein motor complex
has not yet been demonstrated. Our group is developing
strategies to overcome the limited diffusion of gene delivery
nanoparticles by incorporating elements that actively recruit
the dynein motor complex for retrograde intracellular
transport (Fig. 5). We recently evaluated the ability of a
peptide that binds the 8-kDa light chain of the dynein motor
complex (88), and are currently investigating peptides that
bind to other light chain subunits.
Fig. 3. The internalization of nonviral vectors can be accomplished
specifically via receptor targeting (a) or nonspecifically through
electrostatic attractions between positively charged gene carriers and
negatively charged groups on the neuronal plasma membrane (b).
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Given the postmitotic nature of neurons, the nuclear
import of therapeutic plasmid DNA is an important prereq-
uisite for efficient transgene expression. There have been
numerous attempts to incorporate nuclear localization signal
(NLS) peptides into nonviral gene carriers as a means to
promote nuclear import (reviewed recently by van der Aa
et al.( 89)). However, a consensus regarding how to most
effectively incorporate NLS peptides into nonviral vehicles
has not been reached. Furthermore, attempts to improve
nonviral gene delivery to postmitotic cells by incorporating
NLS peptides have resulted in modest increases in gene
expression at best. Clearly, the ability of viruses to efficiently
deliver genetic material into host cell nuclei has not yet been
successfully reproduced in nonviral systems. Consequently,
nuclear entry remains one of the most challenging barriers
hindering the development of nonviral gene carriers in
applications requiring delivery to postmitotic cells.
In contrast to plasmid delivery, the potential delivery of
siRNA to neurons using nonviral carriers would not be
hindered by the requirement for nuclear entry. Since the site
of RNAi activity is hypothesized to be perinuclear (90),
vectors that can efficiently deliver siRNA to the cell body
should mediate successful gene knockdown. As several
studies have recently demonstrated the ability of viruses to
deliver DNA encoding shRNA to neurons, resulting in
functional improvement in models of spinocerebellar ataxia,
Huntington_s disease, amyotrophic lateral sclerosis, and
Alzheimer_s disease (17–20), it is anticipated that nonviral
carriers incorporating siRNA can also be applied toward a
number of neurodegenerative disease conditions.
Control of Gene Expression
After gene carriers successfully deliver DNA to the host
cell nucleus, the control of gene expression is critical to
maintain the appropriate levels of therapeutic factors. While
insufficient expression levels or durations can lead to
suboptimal dosing of the therapeutic transgene, it can be
equally detrimental to express too much transgene product.
For example, high levels of NGF expression in the brain can
cause sensory neurite ingrowth (91). Excessive or long-lasting
expression of GDNF can lead to detrimental effects such as
aberrant fiber sprouting and decreased dopamine production,
minimizing functional recovery (92,93). Consequently, for
some applications, less efficient nonviral vectors may offer
transgene expression levels within the optimal therapeutic
window. Select nonviral vectors are also a viable option for
treatment schemes requiring long-term expression. For
example, Shi et al. demonstrated that repeated intrathecal
administration of polyplexes formulated with PEG-grafted
PEI resulted in prolonged transgene expression in the spinal
cord (29). However, the design of vectors that transfect
specific cell populations and which can be precisely regulated
remains to be achieved.
Two approaches have been employed in nonviral
systems for controlling transgene expression at the level of
cell populations. First, the incorporation of neuron-specific
promoters has been shown to limit gene expression to
neuronal populations (11,26). This strategy is useful when
delivering formulations lacking cell-specific targeting ligands,
as they have been shown to transfect cells in the CNS
indiscriminately. However, since gene delivery materials can
be toxic, it would be preferable to limit the internalization of
material to targeted neuronal cells. Indeed, various strategies
for targeting the delivery of nonviral gene carriers to specific
cell populations through the display of specific targeting
ligands have been explored and are described in previous
sections of this article. As an additional measure, more
precise control over expression levels once vectors have
delivered DNA to targeted neuronal populations may benefit
from plasmid engineering. Plasmid engineering strategies in
nonviral gene therapy were recently reviewed by van Gaal et
al. (94), and have the potential to improve the level and
duration of transgene expression. We predict that nonviral
vectors formulated with engineered plasmids susceptible to
external regulation may provide a means to maintain protein
expression levels within the therapeutic window.
Fig. 5. Concept of a dynein-binding peptide. Synthetic gene carriers
can be modified with dynein-binding peptides to mediate attachment
to the dynein motor complex and active retrograde transport toward
the neuronal nucleus.
Fig. 4. Vehicles delivered to the distal ends of neurites must undergo
active retrograde transport either inside of vesicles (a) or through
direct interaction with microtubule-based motor proteins (b).
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The success of neuronal gene therapy is dependent on
the accessibility of delivery vectors to targeted cells in the
central nervous system (CNS). The central nervous system
(CNS) plays a critical role in directing harmonious function
to organs in the body. Therefore, the CNS is well-protected
from the environment. A series of membranes called the
meninges envelop the brain and spinal cord. These organs are
further protected from physical injury by the skull and
vertebrae, respectively. The CNS is also protected from
passive access of blood-borne proteins, toxins or pathogens
by the closely inter-connected capillary endothelial cells
which form the blood-brain barrier (BBB) (95). These
physical barriers of the CNS therefore also restrict access
for most therapeutic interventions (96). Ideally, gene therapy
strategies that target the CNS will result in efficient delivery
to targeted neurons while avoiding invasive administration
routes that could damage nervous tissue. Although neuro-
tropic viruses such as herpes simplex virus have been used
successfully in several animal models of CNS disease,
nonviral gene therapy is largely hindered by inadequate
methods of non-invasive delivery coupled with inefficient
transgene expression of delivered materials. Therefore, the
development of improved nonviral gene carriers will require
a better understanding of the barriers encountered upon in
vivo administration. The major administration routes for
delivering nucleic acids to neurons in the CNS are illustrated
in Fig. 6. Ultimately, the extracellular barriers encountered
by gene carriers will depend on the route of administration,
as summarized in the following sections.
Direct Administration to the CNS
Intraparenchymal Direct Injection
The neuronal populations affected by neurological
disease may reside in a defined anatomical region of the
brain. For example, Parkinson_s disease is associated with
degeneration of dopaminergic neurons in the substantia nigra
(97) and Huntington_s disease affects neurons in the striatum
and neocortex (98). In such cases, delivery of therapeutic
agents can be accomplished through localized administration
methods. Intracranial direct injection is the simplest, but the
most invasive, method employed for localized gene delivery
to the brain. In this method, vectors are introduced inside or
near the subpopulation of cells where the therapeutic
outcome is required. Although invasive, this administration
method is particularly viable for treatment of malignant brain
tumors (99,100), especially in cases when the administration
of therapeutic genes can be performed in combination with
surgical tumor resection. Additionally, direct injection of
therapeutics can be performed in combination with the
implantation of deep brain electrodes for the treatment of
Parkinson_s disease (101).
Intracranial injection has been used with varying degrees
of success for introducing nonviral gene carriers to the CNS.
Injection of naked DNA requires high doses and results in
minimal gene expression, restricted expression areas, and
non-specific expression in nearby glial cells and neurons
(102). Attempts to improve transgene expression by physical
bombardment of DNA-coated gold colloids resulted in
astrocyte transfection because the uppermost layer of cere-
brum reachable by gene gun delivery is comprised mainly of
glial cells (103). Early studies with PEI established the
feasibility of localized CNS gene delivery by direct brain
injection into the cerebral cortex, hippocampus, and hypo-
thalamus, resulting in transgene expression in neurons and
glia (26). Since that pioneering work, targeted nonviral
systems have been evaluated for more neuron-biased deliv-
ery (10,104). For example, Martinez-Fong and colleagues re-
cently demonstrated successful treatment in a rat model of
Parkinson_s disease by intranigral injection of neurotensin-
modified PLL vectors encoding GDNF (10). Targeted li-
poplexes and peptide-based delivery vectors have also been
successfully administered via intracranial injection (54,104).
The major drawbacks of direct intracranial injection are
local trauma to the brain neuropil, inflammation and toxicity,
as well as limited diffusion of vectors from the injection site.
Indeed, intrastriatal injection of liposomes encapsulating a
reporter gene resulted in local expression only in the area
immediately surrounding the injection site (105). There have
been several attempts using mathematical modeling to
predict the distribution of drugs delivered by local injection
into the brain (106). This information would be important in
designing new drug delivery technologies for the CNS. A
finite element model was developed based on transport of
magnetic resonance imaging markers tracked in brain and
used to predict transport of interleukin-2 in brain (107).
However, more precise consideration of the properties of
nanoparticles is required for better prediction of nonviral
gene delivery due to their larger size and natural heteroge-
neity in physicochemical properties.
Convection-Enhanced Delivery
The limited diffusion of vectors following direct injec-
tion into the brain parenchyma can be alleviated by exploit-
ing convective flow in the brain (108). Pressure gradients
generated by convection-enhanced delivery (CED) increase
interstitial flow, which in turn facilitate effective delivery of
therapeutics throughout the brain with little physical or
functional damage (100). Mechanistic studies have demon-
strated that the CED-based approach is associated with
perivascular transport in the brain, which is generated by
arterial pulsation (109–111). The distribution of drugs
delivered to the brain by CED is affected by infusion volume,
rate, and cannula size, but is not influenced by the molecular
weight, diffusivity, or concentration of the infusate (112).
Therefore, it is likely that CED can achieve a wider distri-
bution of nanoparticles like polyplexes or lipoplexes in the
brain.
The improved distribution of liposomes delivered by
CED has been verified by magnetic resonance imaging
(MRI) (113). In contrast to diffusion-limited distributions
observed from single, low-pressure injections, liposomes
administered by CED were shown to infiltrate large areas
of nervous tissue. A systematic characterization has been
completed to determine the effect of osmolarity of buffer as
well as size and surface properties of model polystyrene
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adeno-associated viruses and adenoviruses on distribution in
CNS (111,114). Nonspecific binding was found to be a major
limitation in broad tissue distribution, even when vectors
were administered by CED. Mathematical modeling of CED
demonstrated that positively charged liposomes have 50-fold
stronger binding affinity toward surrounding tissue than
neutral liposomes, resulting in suboptimal particle penetra-
tion into tissue. To address this issue, a wider distribution can
be achieved by coating nanospheres with anionic albumin or
by modifying the surface of cationic liposomes with poly
(ethylene glycol) (111).
Several variations of conventional CED have been
recently explored. Microfluidics-mediated CED has been
developed to reduce the tissue damage and backflow
associated with injection needles or cannulae used for CED
(115). An innovative application of CED was recently
described to direct systemically-delivered materials to the
CNS (116). A microdialysis catheter was used to create a
local osmotic gradient, which facilitated extravasation of
macromolecules through the blood-brain barrier. This meth-
od, termed retro-CED (R-CED), caused extravasation of
systemically delivered liposomes into tumor tissue in the
brain, suggesting that R-CED might be useful to improve
drug efficacy for anti-tumor therapy.
Intraventricular Injection
While intracerebral injection is appropriate for thera-
peutic interventions that require gene expression in specific
regions of the brain, alternative administration methods are
necessary to achieve a more global distribution of vectors or
gene products throughout the CNS. Intraventricular injection
involves introduction of therapeutic agents into the cerebro-
Fig. 6. Representative administration routes for neuronal gene delivery in vivo: intraparenchymal injection (a), intrathecal injection (b),
intramuscular injection (c).
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Using this method, vectors can distribute to cells lining the
ventricular and subarachnoid space. Gene products secreted
by these cells, such as growth factors, angiogenesis factors,
and nitric oxide synthase (NOS) can ideally be released into
the CSF and circulate through the brain for maximal efficacy
(117).
In one example of intraventricular delivery, lipoplexes
containing a reporter gene or heat shock protein HSP70 were
infused into the lateral ventricle. Stereological analysis of
gene expression after coronal sectioning demonstrated a
longitudinal distribution of transgene expression, including
expression in neurons as determined by cell morphology and
adjacent section staining with NeuN antibodies (118,119).
The administration of neurotrophins such as nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), neurotrophin-4 (NT-4) has been
extensively used to treat CNS injury and disease (54,120).
As an alternative gene-based approach, lipoplexes encoding
NGF were administered by intraventricular injection in a
model of traumatic brain injury. Secretion of NGF into the
CSF resulted in recovery of choline acetyltransferase func-
tion in cholinergic neurons (121). It should be noted,
however, that genes delivered by lipoplexes are typically
expressed in both neurons and glial cells near the injection
site.
Intrathecal Injection
Intrathecal injection, delivery of materials to the intra-
thecal space surrounding the spinal cord, is an alternative
fluid-phase delivery route to the CNS (122). Intrathecal
administration causes minimal pain to patients and affords
larger volume of therapeutic materials than intracranial
injection. In contrast to intracranial injection, intrathecal
injection of nanoparticles results in significantly more wide-
spread distribution throughout the CNS (105). The Wang
group has demonstrated gene delivery to neurons in the CNS
by intrathecal injection of polyplexes composed of PEI and
its derivatives (28,29,41,53,123). Intrathecal delivery of PEI
polyplexes resulted in transgene expression in neurons of the
dorsal root ganglia at levels comparable to those achievable
using baculovirus or adeno-associated virus. Transfection
could be further improved by the addition of targeting
ligands or by PEGylation to reduce particle size (53,113). In
addition, biodegradable vectors introduced by intrathecal
injection have also mediated transgene delivery to neurons
(50).
Peripheral Administration for Neuron Delivery
As an alternative to direct CNS injection, delivery
vectors could hypothetically be administered peripherally
and routed to the CNS post-injection. Peripheral administra-
tion, including intramuscular and intravenous injection,
offers the advantages of safer and less invasive delivery as
well as the possibility of larger injection volumes and
multiple dosages. However, the therapeutic effect achievable
by these approaches has been greatly limited due restricted
access to the CNS as well as high systemic clearance of
vectors.
Intramuscular Injection
Intramuscular (IM) injection is an attractive administra-
tion route for nonviral gene carriers because retrograde
transport along motor neurons could (1) utilize a minimally
invasive way to introduce foreign genes into the CNS and (2)
circumvent the blood-brain barrier (BBB). Proof-of-concept
studies involving tongue injection of polyplexes have shown
retrograde transport of carriers, resulting in gene expression
in the brain stem (55). To enhance the efficiency of
retrograde transport of gene carriers in long-range motor
neurons, several groups have investigated vectors derivatized
with retrogradely transported proteins such as tetanus toxin
C or various neurotrophic factors (40,124). The non-toxic
fragment C of tetanus toxin (TTC) has been reported to bind
to axon terninals at the neuromuscular junction and undergo
efficient retrograde transport (125). GDNF and brain-de-
rived neurotrophic factor (BDNF) have also been shown to
be retrogradely transported in motor neurons, similar to
tetanus toxin (126); these proteins therefore are also poten-
tial ligand candidates for retrograde transport. An interesting
approach utilized PLL conjugated to the monoclonal anti-
body (MC192) against neurotrophic receptor, p75
NTR, for
receptor-mediated retrograde transport (52). The polyplexes
were delivery by injection into the hind limb of newborn rats
or by placing a gel foam formulation on a transected
hypoglossal nerve in adult rats. Transgene expression of
GDNF was detected in both methods, and resulted in rescue
of injured neurons.
Thus, intramuscular delivery of polyplex via retrogradely
transported carriers in motor neurons is a promising ap-
proach to minimally invasive gene delivery. However, most
assessments have utilized hind limb injection in newborn
animals or tongue injection. Ultimately, demonstration of
peripheral delivery from a more distal site and to neurons
with fully developed synapses is important for clinically
relevant demonstration of this technology. Finally, it is
important to consider that, in some neurodegenerative
diseases, impaired retrograde transport is a hallmark of the
disease pathology (127). In such cases, direct CNS delivery is
required to reach targeted neurons.
Intravenous Injection
There is an increasing demand for effective delivery
strategies for the brain because advances in pharmaceutical
technology have resulted in treatment opportunities for
neurological diseases. Intravenous (IV) delivery is a well-
established approach to introduce drugs or therapeutic
genetic materials throughout the body since this route has
minimal limitations on administration dose and accommo-
dates repeated administration (128). For these applications,
nonviral vectors offer the potential advantage over viral
vectors of avoiding an immune response. However, nonviral
gene carriers administered intravenously must overcome
several obstacles before successfully reaching the brain.
Interaction with serum proteins in the blood circulation
compromises targeting and therapeutic efficacy of nonviral
gene carriers by eclipsing targeting ligands or mediating
opsonization and clearance from the circulation. Moreover,
aggregation of vectors in the bloodstream can result in
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hydrophilic groups such as dextran, PEG, or poly(vinyl
pyrrolidone) to nanoparticles helps prevent non-specific
binding with serum proteins and resulting aggregation (129).
The BBB, consisting of endothelial cells connected by
tight junctions in the brain capillaries, poses a formidable
challenge against the effective delivery of therapeutic genes
to the CNS by severely limiting extravasation of delivery
vectors (99,130–132). The tight-junctions between endothelial
cells and the physical and molecular barriers of the adjacent
pericytes and astrocytic endfeet can be temporarily permea-
bilized by utilizing osmotic disruption with intracarotid
hypertonic mannitol (133) or vasoactive compounds
(134,135). However, the safety of this approach has been
raised as a concern because BBB disruption may cause brain
toxicity due to leaking plasma proteins, thus potentially
causing pathological changes (136–138).
Receptor-mediated transcytosis (RMT) has been investi-
gated as an alternative strategy for crossing the BBB. Brain-
specificsystemicdeliverysystemsbasedonantibody-andPEG-
conjugated liposomes, called PEGylated immunoliposomes
(PIL), has been extensively explored by the Pardridge group
(139–142). The monoclonal antibodies employed target recep-
tors on the brain endothelial cells such as transferrin or the
insulin receptor. Brain-specific expression has been mediated
by PILs following IV injection (141). In another promising
study, intravenous delivery of a tyrosine hydroxylase (TH)-
expressing plasmid formulated with transferrin-targeted PILs
normalized TH protein levels in the striatum and alleviated
motor impairment in a rat model of Parkinson_s disease (39).
CONCLUSIONS
Considering the numerous barriers encountered in appli-
cations of neuron-targeted nucleic acid delivery, the design of
effective nonviral vehicles will require an integrated approach
that accounts for each of the barriers. Understanding of the
barriersencountered bynonviral vectorsmay inspire the design
of improved nonviral vectors that can be tailored to specific
applications of neuronal nucleic acid delivery. Ultimately, we
envision the design of a multicomponent vector that remains
stable upon in vivo administration, which incorporates func-
tionalities for neuron targeting, endosomal escape, retrograde
transport, and subcellular localization, and which can be
tailored toward specific CNS-targeted delivery applications.
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